Sorry, you need to enable JavaScript to visit this website.

A Study of PF-06700841 to Determine the Beneficial Effect at 16 Weeks and the Safety and Beneficial Effect up to 1 Year in Subjects with Active Psoriatic Arthritis

A Study of PF-06700841 to Determine the Beneficial Effect at 16 Weeks and the Safety and Beneficial Effect up to 1 Year in Subjects with Active Psoriatic Arthritis. A Phase 2b, Randomized, Double-Blind,
Placebo-Controlled Study of PF-06700841 to Evaluate the Efficacy at 16 Weeks and to Evaluate the Safety
and Efficacy up to 1 Year in Subjects with Active Psoriatic Arthritis.

Category & Conditions: Immune System Diseases and Conditions
Medicine: brepocitinib (PF-06700841)
ClinicalTrials.gov Identifier (NCT): NCT03963401
Protocol ID: B7931030
    Share
PrintDownload
Open Plain Language Summary Result: Click here